Drug Firms Must Speed Major Trial Risk Reports - FDA; Rule Requires More Notification of Safety Problems

WASHINGTON, Sept 28 (Reuters) - Drugmakers studying experimental drugs in anticipation of U.S. sales must now tell regulators about serious health problems that arise during clinical trials within about two weeks.

MORE ON THIS TOPIC